Head and Neck Cancer: New Drug Combinations

We are studying a new combination of drugs for patients with recurrent or metastatic head and neck cancer. The goal is to see if this combination works better than the current treatment options.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Carboplatin
Carboplatin is a chemotherapy substance used to treat various cancers by damaging cancer cells and slowing tumor growth.
Durvalumab
Durvalumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein tumors use to hide.
Paclitaxel
Paclitaxel is a substance used in chemotherapy to treat various cancers by preventing cancer cells from dividing.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Zimberelimab
Domvanalimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
Oncology
Bordeaux, France
Centre Leon Berard
Oncolog
Meyzieu, France
Institut Curie
Oncology
Paris, France

Sponsor: Gilead Sciences Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.